USP25 and cancer: Genetic depletion of USP25 expression or pharmacological inhibition of the DUB causes decreases in the expression levels of KRAS (WT or mutants) and in the strength of KRAS downstream signaling, resulting in reduced rates of cancer cell proliferation (Fig. 7).